ALKS Margin reged Alkermes PLC

ALKS (Alkermes PLC) - tandha merek perusahaan

This gross margin chart illustrates operating profitability dynamics, where the 79.40 metric determines this level. Alkermes plc (ALKS) generates revenue from the sale of prescription medications for CNS and addiction therapy. The company covers the global schizophrenia treatment market, leveraging its own patents and licensing royalties. High scientific authority and physician trust provide the brand with a stable reputation in psychiatry.

Rentabilitas reged: alkermes.com (ALKS) kanggo 04.07.2022 - 19.11.2026

Rincian metrik keuangan lan pasar Alkermes PLC (ALKS)

- rega saham lan konsensus proyeksi valuasi:
Analisis dhasar perusahaan:ALKS - Alkermes Inc.
Barang utama Alkermes

To distinguish a fundamentally resilient business from speculative assets, it is critical for investors to evaluate the portion of revenue remaining after covering direct production costs. By analyzing the gross profit margin, one can determine the ability of Alkermes plc (ALKS) to maintain margins amidst patent risks and raw material import disruptions, which directly confirms the operational efficiency and long-term viability of the biopharmaceutical model.